Sorted By Test Name - Mayo Medical Laboratories

HYPOG
82439
Thermoactinomyces vulgaris, Micropolyspora faeni, Aspergillus fumigatus). The immunopathogenesis of
disease is not known; but, several immunologic mechanisms may play a role in producing alveolitis,
including cellular immunity mediated by CD4 and CD8 T-lymphocytes, immune-complex mediated
inflammation, complement activation or activation of alveolar macrophages.(1) HP is suspected clinically
in patients who present with intermittent or progressive pulmonary symptoms and interstitial lung disease.
The diagnosis is established by compatible clinical and radiographic findings, pulmonary function tests,
and demonstration of specific antibodies to organic antigens known to cause the disease.
Useful For: Evaluation of patients suspected of having hypersensitivity pneumonitis induced by
exposure to Aspergillus fumigatus, Thermoactinomyces vulgaris, or Micropolyspora faeni
Interpretation: Elevated concentrations of IgG antibodies to Aspergillus fumigatus,
Thermoactinomyces vulgaris, or Micropolyspora faeni in patients with signs and symptoms of
hypersensitivity pneumonitis is consistent with disease caused by exposure to 1 or more of these organic
antigens. Extreme elevations (>5 times the upper limit of normal) occur in some patients with active
disease.(2)
Reference Values:
Aspergillus fumigatus, IgG ANTIBODIES
or =4 years: < or =102 mg/L
Micropolyspora faeni, IgG ANTIBODIES
0-12 years: < or =4.9 mg/L
13-18 years: < or =9.1 mg/L
>18 years: < or =13.2 mg/L
Thermoactinomyces vulgaris, IgG ANTIBODIES
0-12 years: < or =6.6 mg/L
13-18 years: < or =11.0 mg/L
>18 years: < or =23.9 mg/L
Clinical References: 1. Fink JN, Zacharisen MC: Hypersentivity pneumonitis. In Allergy Principles
and Practice. Vol. 1. Fifth edition. Edited by E Middleton, Jr., CE Reed, EF Ellis, et al. St. Louis, MO,
Mosby Year Book, Inc., 1998, Chapter 69 2. Anderson E, Jacob GL, Robert GD, Homburger HA:
Comparative evaluation of enzyme immunoassay and immunodiffusion for detection of IgG antibodies to
hypersensitivity pneumonitis antigens. Poster Presentation, AAAAI Annual Meeting, San Diego, CA,
March 3-8, 2000. J Allergy Clin Immunol 2000;105:S304
Hypoglycemic Agent Screen, Serum
Clinical Information: The metabolic and hormonal profiles of insulinoma and sulfonylurea-induced
hypoglycemia are identical. Therefore, in the evaluation of the hypoglycemic patient, the possible use of
oral hypoglycemic agents as the cause for low blood glucose and elevated plasma insulin must be
considered. Absence of hypoglycemic drugs in blood serum during an episode of low blood glucose
should be demonstrated before considering pancreatic exploration for suspected insulinoma.
Useful For: Evaluation of suspected insulinoma characterized by hypoglycemia and increased plasma
insulin concentration. Detecting drugs that stimulate insulin secretion If hypoglycemia is the result of 1 of
these drugs, the test will detect the drug at physiologically significant concentrations in serum during an
episode of hypoglycemia. Drugs detected by this procedure are: -The first-generation
sulfonylureas-acetohexamide, chlorpropamide, tolazamide, and tolbutamide -The second-generation
sulfonylureas--glimepiride, glipizide, and glyburide -The meglitinide-repaglinide Drugs designed to make
tissues more sensitive to insulin that do not induce hypoglycemia, such as pioglitazone, rosiglitazone, and
troglitazone (recently withdrawn from the United States market) are not included in this screen test. Drugs
that lower blood glucose through mechanisms not related to stimulation of insulin secretion, such as
acarbose, metformin, and miglitol are not included in this screen test.
Current as of January 4, 2013 7:15 pm CST 800-533-1710 or 507-266-5700 or MayoMedicalLaboratories.com Page 995